Last reviewed · How we verify
PF-07321332 Dose 5 (pf-07321332-dose-5)
PF-07321332 is an investigational antiviral drug developed by Pfizer Inc. for the treatment of COVID-19. It is designed to inhibit the main protease (Mpro) of SARS-CoV-2, which is essential for viral replication. The drug is being evaluated in various clinical trials, including Phase 2/3 studies, and has shown promising results in reducing viral load and improving clinical outcomes. However, it does not have an FDA label yet, and its safety and efficacy are still under investigation. Common side effects include diarrhea, headache, and muscle pain, but the overall safety profile appears favorable compared to placebo.
At a glance
| Generic name | pf-07321332-dose-5 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Protease inhibitor |
| Target | Main protease (MPro) of SARS-CoV-2 |
| Phase | FDA-approved |
| First approval | Pending regulatory approval |
Approved indications
- COVID-19
Pipeline indications
Common side effects
Drug interactions
- Atazanavir
- Cobicistat
- Darunavir
- Dolutegravir
- Etravirine
- Indinavir
- Lopinavir
- Nelfinavir
- Ritonavir
- Saquinavir
- Tipranavir
- Darunavir/Cobicistat
Key clinical trials
Patents
| Patent | Expiry | Type |
|---|---|---|
| US10961144B2 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |